The iFuse Bedrock Granite implant is designed for sacroiliac fusion and sacropelvic fixation and received the FDA’s breakthrough device designation, according to an April 19 news release.
Approval for the payment is subject to FDA clearance and finalization of the proposed rule. The CMS payment will help widen access to Medicare patients.
